At a glance
ClinicalIndex Comparison RecordN/ACompleted· 269 enrolled
Drug / intervention
Prodigy, Prodigy MRI or Proclaim Elite IPGdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-center Prospective Study Determining the Sustainability of Pain Relief and Psychosocial and Functional Responses When Utilizing a Multiple Waveform Enabled Neurostimulator
In Brief
A clinical study evaluating Prodigy, Prodigy MRI or Proclaim Elite IPG for Chronic Pain and Intractable Pain. Completed, enrolled 269 participants across 22 sites in 7 countries.
Detailed Summary
The TRIUMPH study is a post-market, international, multicenter, interventional, prospective, single-arm study intended to evaluate the sustainability of pain control and psychosocial and functional responses utilizing a multiple-waveform enabled neurostimulator in subjects with chronic, intractable pain of the trunk and/or limbs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pain, Intractable Pain
CountriesCanada, Finland, Germany, Italy, Spain, Switzerland, United States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
First PostedMar 2017
Primary CompletionJan 2019
Study CompletionAug 2020
TodayJul 2026
First PostedMar 17, 2017
Enrollment StartMar 3, 2017
Primary CompletionJan 24, 2019
Study CompletionAug 26, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.3 years ago
Interventions
Prodigy, Prodigy MRI or Proclaim Elite IPGdevice
Subjects will be permanently implanted with either a Prodigy, Prodigy MRI or Proclaim Elite IPG